Back to Journals » Vascular Health and Risk Management » Volume 5

Amlodipine and valsartan as components of a rational and effective fixed-dose combination

Authors Waeber B

Published 27 March 2009 Volume 2009:5 Pages 165—174

DOI https://doi.org/10.2147/VHRM.S3134

Review by Single-blind

Peer reviewer comments 2

Bernard Waeber1, Luis M Ruilope2

1Division of Clinical Pathophysiology, University Hospital, Faculty of Biology and Medicine, University of Lausanne, Switzerland; 2Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain

Abstract: Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are widely used today to initiate antihypertensive therapy but, when given as monotherapy, do not suffice in most patients to normalize blood pressure. Combining the two types of agents considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. This is exemplified by the experience accumulated with the recently developed fixed dose combination containing the AT1-receptor blocker valsartan (160 mg) and the dihydropyridine amlodipine (5 or 10 mg). In a randomized trial, an 8-week treatment normalized blood pressure (<140/90 mmHg) within 8 weeks in a large fraction of hypertensive patients (78.4% and 85.2% using the 5/160 [n = 371] and 10/160 mg [n = 377] dosage, respectively). Like all AT1-receptor blockers valsartan has a placebo-like tolerability. Valsartan prevents to a large extent the occurrence amlodipine-induced peripheral edema. Both amlodipine and valsartan have beneficial effects on cardiovascular morbidity and mortality, as well as protective effects on renal function. The co-administration of these two agents is therefore very attractive, as it enables a rapid and sustained blood pressure control in hypertensive patients. The availability of a fixed-dose combination based on amlodipine and valsartan is expected therefore to facilitate the management of hypertension, to improve long-term adherence with antihypertensive therapy and, ultimately, to have a positive impact on cardiovascular and renal outcomes.

Keywords: antihypertensive therapy, fixed-dose combination, calcium antagonists, angiotensin receptor blockers, blood pressure control, tolerability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes

Sandra Beer, François Feihl, Juan Ruiz, Irène Juhan-Vague, Marie-Françoise Aillaud, et al

Vascular Health and Risk Management 2008, 4:1449-1458

Published Date: 5 December 2008

Readers of this article also read:

Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units

Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Janson C, Sandström T

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:173-183

Published Date: 22 January 2015

Can dynamic contour tonometry and ocular pulse amplitude help to detect severe cardiovascular pathologies?

Bertelmann T, Langanke S, Potstawa M, Strempel I

Clinical Ophthalmology 2014, 8:1317-1321

Published Date: 14 July 2014

Comorbidity and survival of Danish patients with colon and rectal cancer from 2000–2011: a population-based cohort study

Ostenfeld EB, Nørgaard M, Thomsen RW, Iversen LH, Jacobsen JB, Søgaard M

Clinical Epidemiology 2013, 5:65-74

Published Date: 1 November 2013

Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α

Manoharan Y, Ji Q, Yamazaki T, Chinnathambi S, Chen S, Ganesan S, Hill JP, Ariga K, Hanagata N

International Journal of Nanomedicine 2012, 7:3625-3635

Published Date: 16 July 2012

Costs and outcomes of noncardioembolic ischemic stroke in a managed care population

Nicole M Engel-Nitz, Stephen D Sander, Carolyn Harley, et al

Vascular Health and Risk Management 2010, 6:905-913

Published Date: 5 October 2010

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation

Gerald V Naccarelli, Frank Peacock

Vascular Health and Risk Management 2009, 5:783-791

Published Date: 11 September 2009

Fibrinogen as a risk factor for premature myocardial infarction in Iranian patients: A case control study

Mohammad Shojaie, Morteza Pourahmad, Ahad Eshraghian, et al

Vascular Health and Risk Management 2009, 5:673-676

Published Date: 11 August 2009

Overweight, physical activity and high blood pressure in children: a review of the literature

Brian Torrance, K Ashlee McGuire, Richard Lewanczuk, Jonathan McGavock

Vascular Health and Risk Management 2007, 3:139-149

Published Date: 15 March 2007